文献速递中医骨伤中药与中成药合理使用中医康复

术后加味腰痛汤与单侧双通道内镜腰椎间盘突出症早期康复的关联:倾向评分加权回顾性队列研究

Association of postoperative modified Yaotong Tang with early recovery after unilateral biportal endoscopy for lumbar disc herniation: a retrospective comparative cohort study using propensity score weighting.
PubMed 文献 · Front Pharmacol · 2026-07-09

本研究为单中心回顾性比较队列,筛查235例单节段腰椎间盘突出症手术患者,182例符合标准,其中122例纳入UBE主要分析(62例UBE+加味腰痛汤,60例单纯UBE),另60例经椎间孔腰椎椎间融合术队列仅作描述性外部基准。采用逆概率治疗加权调整后,UBE+加味腰痛汤组术后第3天和第7天VAS评分更低,术后第一周IL-6和CRP更低,随访JOA评分更高,未观察到Clavien-Dindo III级及以上不良事件。

要点

  • 术后加味腰痛汤与UBE术后早期疼痛评分更低相关。
  • 术后第一周IL-6和CRP水平在联合组更低。
  • 随访JOA评分联合组更高,无严重不良事件信号。

核心结论

  • 术后使用加味腰痛汤与UBE治疗腰椎间盘突出症后早期疼痛评分更低、炎症标志物水平更低及后续功能恢复更好相关。
  • 未观察到严重安全信号,但因果关系和罕见草药相关安全事件需前瞻性验证。

研究设计与样本

  • 单中心回顾性比较队列研究,筛查235例症状性单节段腰椎间盘突出症手术患者。
  • 182例符合标准,其中122例纳入主要UBE分析队列(62例UBE+加味腰痛汤,60例单纯UBE),60例经椎间孔腰椎椎间融合术队列仅作描述性外部基准。
  • 主要UBE比较采用逆概率治疗加权(IPTW)调整。

主要发现

  • 与单纯UBE相比,UBE+加味腰痛汤组IPTW调整后术后第3天VAS评分更低(3.88 vs. 4.67;平均差-0.79;95% CI -1.06至-0.53;P < 0.001)。
  • UBE+加味腰痛汤组IPTW调整后术后第7天VAS评分更低(2.85 vs. 3.73;平均差-0.88;95% CI -1.14至-0.62;P < 0.001)。
  • 术后第一周IPTW调整后IL-6和CRP水平在UBE+加味腰痛汤组更低。
  • 随访日本骨科协会(JOA)评分在UBE+加味腰痛汤组更高。
  • 未观察到Clavien-Dindo III级或以上不良事件。

临床怎么用

  • 对于接受UBE的腰椎间盘突出症患者,术后可考虑联合加味腰痛汤以改善早期疼痛和炎症反应。
  • 需注意本研究为回顾性设计,因果关系未确定,应用时应个体化评估。

局限性

  • 回顾性研究设计,可能存在残余混杂。
  • 单中心研究,样本量有限。
  • 罕见草药相关安全事件需前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Modified Yaotong Tang (MYT) is used as an adjunctive postoperative herbal decoction in traditional Chinese medicine practice for lumbar disorders, but its association with early recovery after unilateral biportal endoscopy (UBE) and the reproducibility of its clinical preparation remain insufficiently characterized. METHODS: This single-center retrospective comparative cohort study screened 235 patients with symptomatic single-level lumbar disc herniation (LDH) who underwent surgical treatment between September 2022 and September 2025. Of these, 182 met the eligibility criteria, including 122 patients in the primary UBE analytic cohort (62 UBE + MYT and 60 UBE alone) and 60 patients in a transforaminal lumbar interbody fusion cohort retained only as a descriptive external benchmark. The primary UBE comparison was adjusted using inverse probability of treatment weighting (IPTW). RESULTS: Compared with UBE alone, the UBE + MYT cohort showed lower IPTW-adjusted Visual Analog Scale scores at postoperative day (POD) 3 (3.88 vs. 4.67; mean difference, -0.79; 95% CI, -1.06 to -0.53; P < 0.001) and POD7 (2.85 vs. 3.73; mean difference, -0.88; 95% CI, -1.14 to -0.62; P < 0.001). IPTW-adjusted IL-6 and CRP levels were lower during the first postoperative week, and follow-up Japanese Orthopaedic Association scores were higher in the UBE + MYT cohort. MYT administration was verified using de-identified medical, pharmacy/decoction-room, nursing, and follow-up records. No Clavien-Dindo grade III or higher adverse events were observed. DISCUSSION: Postoperative MYT use was associated with lower early postoperative pain scores, lower inflammatory biomarker levels, and better subsequent functional recovery after UBE for LDH. No severe safety signal was observed, but causality and rare herb-related safety events require prospective validation.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Xie M, Huang X, Wang H, et al. Association of postoperative modified Yaotong Tang with early recovery after unilateral biportal endoscopy for lumbar disc herniation: a retrospective comparative cohort study using propensity score weighting. Front Pharmacol. 2026. PMID: 42494529. doi:10.3389/fphar.2026.1852732

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。